Rational design of a potent pan-pim kinases inhibitor with a rhodanine-benzoimidazole structure

Anticancer Research

Volumn 37, Issue 8, 2017, Pages 4051-4057

  Sawaguchi, Yuichi ^a   Yamazaki, Ryuta ^a   Nishiyama, Yukiko ^a   Sasai, Toshio ^a   Mae, Masayuki ^a   Abe, Atsuhiro ^a   Yaegashi, Takashi ^a   Nishiyama, Hiroyuki ^a   Matsuzaki, Takeshi ^a  

^a YAKULT CENTRAL INSTITUTE FOR MICROBIOLOGICAL RESEARCH   (Japan)

Author keywords

Anticancer activity; Docking analysis; Pim kinases inhibitors; Rhodanine benzoimidazole; Rhodanine benzylidene

Indexed keywords

5 (3 ETHOXY 4 HYDROXYBENZYLIDENE) 2 THIOXOTHIAZOLIDIN 4 ONE; BENZOIMIDAZOLE; IMIDAZOLE DERIVATIVE; PROTEIN KINASE PIM 1; PROTEIN KINASE PIM 2; PROTEIN KINASE PIM 3; PROTEIN SERINE THREONINE KINASE; PROTEIN SERINE THREONINE KINASE INHIBITOR; RHODANINE; UNCLASSIFIED DRUG; ENZYME INHIBITOR; MOLECULAR LIBRARY; PROTEIN KINASE INHIBITOR;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; APOPTOSIS ASSAY; ARTICLE; BLOOD CANCER CELL LINE; CANCER CELL LINE; CELL ACTIVITY; CELL CYCLE PROGRESSION; CELL PROLIFERATION; DRUG DESIGN; DRUG IDENTIFICATION; ENZYME INACTIVATION; FLUORESCENCE ACTIVATED CELL SORTING; IC50; IMMUNOBLOTTING; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SOLID MALIGNANT NEOPLASM; WESTERN BLOTTING; ADMINISTRATION AND DOSAGE; ANTAGONISTS AND INHIBITORS; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; ENZYMOLOGY; GENETICS; HUMAN; MOLECULAR LIBRARY; NEOPLASMS; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; ENZYME INHIBITORS; HUMANS; NEOPLASMS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-PIM-1; RHODANINE; SIGNAL TRANSDUCTION; SMALL MOLECULE LIBRARIES;

EID: 85026197673     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: 10.21873/anticanres.11790     Document Type: Article

References (28)

1. Amaravadi R and Thompson CB: The survival kinases Akt and Pim as potential pharmacological targets. J Clin Invest 115: 2618-2624, 2005.
2. Saurabh K, Scherzer MT, Shah PP, Mims AS, Lockwood WW, Kraft AS and Beverly LJ: The PIM family of oncoproteins: small kinases with huge implications in myeloid leukemogenesis and as therapeutic targets. Oncotarget 5: 8503-8514, 2014.
3. Eichmann A, Yuan L, Bréant C, Alitalo K and Koskinen, PJ: Developmental expression of pim kinases suggests functions also outside of the hematopoietic system. Oncogene 19: 1215-1224, 2000.
4. Aho TL, Sandholm J, Peltola KJ, Mankonen HP, Lilly M and Koskinen PJ: Pim-1 kinase promotes inactivation of the proapoptotic Bad protein by phosphorylating it on the Ser112 gatekeeper site. FEBS Lett 571: 43-49, 2004.
5. Li YY, Popivanova BK, Nagai Y, Ishikura H, Fujii C and Mukaida N: Pim-3, a proto-oncogene with serine/threonine kinase activity, is aberrantly expressed in human pancreatic cancer and phosphorylates bad to block bad-mediated apoptosis in human pancreatic cancer cell lines. Cancer Res 66: 6741-6747, 2006.
6. Yan B, Zemskova M, Holder S, Chin V, Kraft A, Koskinen PJ and Lilly M: The PIM-2 kinase phosphorylates BAD on serine 112 and reverses BAD-induced cell death. J Biol Chem 278: 45358-45367, 2003.
7. Fox CJ, Hammerman PS, Cinalli RM, Master SR, Chodosh LA and Thompson CB: The serine/threonine kinase Pim-2 is a transcriptionally regulated apoptotic inhibitor. Genes Dev 17: 1841-1854, 2003.
8. Chen WW, Chan DC, Donald C, Lilly MB and Kraft AS: Pim family kinases enhance tumor growth of prostate cancer cells. Mol Cancer Res 3: 443-451, 2005.
9. Mochizuki T, Kitanaka C, Noguchi K, Muramatsu T, Asai A and Kuchino Y: Physical and functional interactions between Pim-1 kinase and Cdc25A phosphatase. Implications for the Pim-1-mediated activation of the c-Myc signaling pathway. J Biol Chem 274: 18659-18666, 1999.
10. Wang Z, Bhattacharya N, Mixter PF, Wei W, Sedivy J and Magnuson NS: Phosphorylation of the cell cycle inhibitor p21Cip1/WAF1 by Pim-1 kinase. Biochim Biophys Acta 1593: 45-55, 2002.
11. Hammerman PS, Fox CJ, Birnbaum MJ and Thompson CB: Pim and Akt oncogenes are independent regulators of hematopoietic cell growth and survival. Blood 105: 4477-4483, 2005.
12. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, Pienta KJ, Rubin MA and Chinnaiyan AM: Delineation of prognostic biomarkers in prostate cancer. Nature 412: 822-826, 2001.
13. Ellwood-Yen K, Graeber TG, Wongvipat J, Iruela-Arispe ML, Zhang J, Matusik R, Thomas GV and Sawyers CL: Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell 4: 223-238, 2003.
14. Santio NM, Salmela M, Arola H, Eerola SK, Heino J, Rainio EM and Koskinen PJ: The PIM1 kinase promotes prostate cancer cell migration and adhesion via multiple signalling pathways. Exp Cell Res 342: 113-124, 2016.
15. Popivanova BK, Li YY, Zheng H, Omura K, Fujii C, Tsuneyama K and Mukaida N: Proto-oncogene, Pim-3 with serine/threonine kinase activity, is aberrantly expressed in human colon cancer cells and can prevent Bad-mediated apoptosis. Cancer Sci 98: 321-328, 2007.
16. Amson R, Sigaux F, Przedborski S, Flandrin G, Givol D and Telerman A: The human protooncogene product p33pim is expressed during fetal hematopoiesis and in diverse leukemias. Proc Natl Acad Sci USA 86: 8857-8861, 1989.
17. Nieborowska-Skorska M, Hoser G, Kossev P, Wasik MA and Skorski T: Complementary functions of the antiapoptotic protein A1 and serine/threonine kinase pim-1 in the BCR/ABL-mediated leukemogenesis. Blood 99: 4531-4539, 2002.
18. Zhang P, Wang H, Min X, Wang Y, Tang J, Cheng J, Li D, Chen X, Cheng F, Wang N and Yang H: Pim-3 is expressed in endothelial cells and promotes vascular tube formation. J Cell Physiol 220: 82-90, 2009.
19. Xie Y, Burcu M, Linn DE, Qiu Y and Baer MR: Pim-1 kinase protects P-glycoprotein from degradation and enables its glycosylation and cell surface expression. Mol Pharmacol 78: 310-318, 2010.
20. Halgren TA: Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94. J Comp Chem 17: 490-519, 1996.
21. Labute P: The generalized Born/volume integral implicit solvent model: Estimation of the free energy of hydration using London dispersion instead of atomic surface area. J Comp Chem 29: 1693-1698, 2008.
22. Allen JD, Verhoeven E, Domen J, van der Valk M and Berns A: Pim-2 transgene induces lymphoid tumors, exhibiting potent synergy with c-myc. Oncogene 15: 1133-1141, 1997.
23. Paíno T, García-Gómez A, González-Méndez L, San Segundo L, Hernández-García S, López-Iglesias AA, Algarín EM, Martín-Sánchez M, Corbacho-González D, Ortiz-de-Solórzano C, Corchete L, Gutiérrez NC, Mateos MV, Garayoa M and Ocio EM: The novel pan-PIM kinase inhibitor, PIM447, displays dual anti-myeloma and bone protective effects, and potently synergizes with current standards of care. Clin Cancer Res 23: 225-238, 2016.
24. Koblish H, Shin N, Hall L, Wen X, O'Connor S, Dostalik V, Wang Q, Wang K, Covington M, Marando C, Bowman K, Boer J, Burke K, Zhang K, Feng H, Xue CB, Li YL, Yao W, Huber R, Vaddi K and Scherle P: Activity of the pan-PIM kinase inhibitor INCB053914 in models of multiple myeloma. Cancer Res 75: 5416, 2015.
25. Keeton EK, McEachern K, Dillman KS, Palakurthi S, Cao Y, Grondine MR, Kaur S, Wang S, Chen Y, Wu A, Shen M, Gibbons FD, Lamb ML, Zheng X, Stone RM, Deangelo DJ, Platanias LC, Dakin LA, Chen H, Lyne PD and Huszar D: AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia. Blood 123: 905-913, 2014.
26. Chen LS, Redkar S, Bearss D, Wierda WG and Gandhi V: Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells. Blood 114: 4150-4157, 2009.
27. Kirschner AN, Wang J, van der Meer R, Anderson PD, Franco-Coronel OE, Kushner MH, Everett JH, Hameed O, Keeton EK, Ahdesmaki M, Grosskurth SE, Huszar D and Abdulkadir SA: PIM kinase inhibitor AZD1208 for treatment of MYC-driven prostate cancer. J Natl Cancer Inst 107: pii: dju407, 2014.
28. Mumenthaler SM, Ng PY, Hodge A, Bearss D, Berk G, Kanekal S, Redkar S, Taverna P, Agus DB and Jain A: Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes. Mol Cancer Ther 8: 2882-2893, 2009.